Buyer Beware|


By Wren Graves, Consequence | Bexson Biomedical’s device currently works with ketamine, and could see human trials as soon as 2022. The perfect dose of psychedelics may differ from person to person, but everyone can agree it lies somewhere between “Is it working?” and “Run! The moon is chasing us!” And as the medicinal benefits of psilocybin, MDMA, DMT, and more become harder for regulators to ignore, scientists are working on better delivery systems. As Vice reports, Bexson Biomedical has developed a wearable pump, based on the same principles as an insulin pump, that would give its users precise control over the length and intensity of their trips.

Bexson co-founders Gregg Peterson and Jeffrey Becker developed their device in response to the opioid crisis, with the hope of “creating a non-opioid therapy that patients can go home with.” It currently works with ketamine, and while human trials may be coming next year, you won’t be able to legally use them recreationally any time soon.

“We are actively developing our psychedelic formulations and would like to have them in humans in 2022,” Peterson said. “We’ve got some work to do beforehand, but that would be our target.”

The device uses a small needle to provide controlled doses of liquid subcutaneously (under the skin, in the fat, before the needle hits muscle). This solves a number of problems with pills, or as they are sometimes called in medicine, bolus doses.
> > > > > > > > >
Read the whole story here:

[Thank you to Alex Teitz,, for contributing this article.]

Leave a Reply

Close Search Window